Ribavirin, a synthetic inhibitor of RNA and DNA virus replication, has displayed considerable chemotherapeutic activity against experimentally induced viral infections and is currently undergoing extensive clinical evaluations in humans (24, 26, 27) . Some of its most promising features are a broad spectrum of activity (the broadest of the currently studied antiviral agents), a relative lack of toxicity for normal or virus-infected host cells, and the failure of viral strains exposed to ribavirin to develop drug resistance. Although ribavirin inhibits replication of some viruses by specifically interfering with RNA polymerases or by preventing the 5'-terminal modification of viral mRNA, several observations suggest the possibility that some of the effectiveness of the drug in vivo may stem from its immunosuppressive activity. For example, ribavirin is most beneficial against influenza and vaccinia virus infections, diseases in which hypersensitivity responses to viral antigens may contribute significantly to pathogenicity (2, 23, 30) . Ribavirin is also active in the treatment of murine systemic lupus erythematosus (10, 11) . More recently, we have shown that administration of ribavirin to mice in a single therapeutic dose (40 mg/kg) inhibits primary immunoglobulin M (IgM) and IgG plaque-forming cell (PFC) responses and suppresses memory cell generation without significant loss of lymphoid cells (19) .
In an attempt to identify the mechanism of immunosuppression, the capacity of ribavirin to alter antigen-dependent PFC responses in cultures of normal and T cell-depleted murine spleen cell populations was examined. The results obtained indicate that ribavirin, at concentrations that are antiviral in vitro, exerted a differential effect on lymphocyte subpopulations participating in antibody responses. Low concentrations (0.1 to 1 ,g/ml) of ribavirin moderately enhanced PFC responses, whereas slightly higher concentrations (5 to 10 ,ug/ml) abolished both primary and secondary PFC responses. Enhancement resulted from selective inhibition of suppressor T cells, whereas the primary targets for the immunosuppressive effects of ribavirin were B cells.
MATERIALS AND METHODS
Mice. C57BL/6 mice of both sexes were purchased from Jackson Laboratories, Bar Harbor, Maine, and housed in cages with barrier filters.
Ribavirin. New England Nuclear Corp.) was added for the final 4 h of incubation. At termination of incubation, cells were harvested and prepared for liquid scintillation counting as described previously (18) . Data from three replicate cultures were used to calculate the mean counts per minute per culture ± the standard error of the mean. Inhibition of proliferation by ribavirin was also expressed as the percentage of control incorporation.
Cell viability. Cells from duplicate cultures were harvested and pooled in glass tubes (12 by 75 mm). Recovered cells were counted with a Coulter electronic cell counter, and percent viability was determined by trypan blue exclusion.
Statistics. Comparisons between PFC and proliferative responses in control and ribavirin-treated cultures and differences in viable cell recoveries were analyzed by Student's t test.
RESULTS
Modulation of primary and secondary PFC responses by ribavirin. Figure 1 illustrates the results of five experiments in which various amounts of ribavirin were added to spleen cell cultures stimulated with T cell-dependent (SRBC) or T cell-independent (LPS) antigens. A significant (P < 0.01) increase in the primary PFC response to SRBC was observed with 1 pug of ribavirin; however, this response decreased progressively with 5, 7.5, and 10 ,ug of ribavirin ( Fig. 1) . No significant reduction in spleen cell recoveries occurred, except in cultures receiving 10 ,ug of ribavirin. Ribavirin also exerted similar dose-dependent effects on the primary PFC response to LPS (Fig. 2) . Enhancement, seen in Fig. 2 with 0.1-and 1-,ug doses, was followed at higher doses by a marked reduction in the PFC response. There was a loss of viable cells at the highest dose tested. By using spleen cells from SRBC-primed mice, secondary IgM and IgG PFC responses were enhanced and suppressed to the same degree by the same doses of ribavirin that modulated the primary PFC responses (data not shown).
Effects of length of exposure to ribavirin on PFC responses. To identify the interval required for ribavirin to exert maximal effects, SRBCstimulated spleen cells were exposed to 1 or 10 ,ug of ribavirin at culture initiation or at various times thereafter. Each exposure was terminated after 24 h by thoroughly washing the spleen cell suspension and culture dishes with fresh tissue culture medium. Spleen cells were then returned to their original dishes and incubated for the remainder of the 5-day culture period. When (Fig. 3) . A 1-,ug dose of ribavirin given from 48 to 72 h was even more successful in enhancing PFC responses than a continuous pulse from 0 to 120 h; however, delaying the addition of ribavirin until 72 or % h after culture initiation had diminished effects. Results from identical experiments, except for the use of 10-jxg doses, resulted in a progressive increase in the suppression of PFC responses that was maximal at 48 to 72 h.
These experiments indicated that the maximal effects of ribavirin occurred 48 to 72 h after culture initiation. Therefore, this time period was selected to assess the lowest exposure of ribavirin necessary to produce the greatest suppressive effects. In addition, because of the ability of guanosine to reverse many of the effects of ribavirin, the same protocol was used to evaluate guanosine interference with ribavirin action. A 10-,ug dose of ribavirin was added 60 h ,u.g of ribavirin at each offive consecutive 24-h periods.
Periods of drug exposure were terminated by harvesting and washing spleen cell cultures as described in the text. The percentage of control response was calculated from cultures not exposed to ribavirin but otherwise treated identically.
ANTIMICROB. AGENTS CHEMOTHER. (the midpoint) after initiation of SRBC-stinmulated spleen cell cultures. After various lengths of time, each exposure period was terminated as described above, and spleen cells were returned to their dishes for the duration of the 5-day incubation. Other cultures were exposed to 10 p,g each of ribavirin and guanosine per ml for the same time periods. When ribavirin or ribavirin and guanosine were either added and removed immediately or left in the cultures for 6 h, IgM PFC responses were not significantly affected (Fig. 4) also shows that, except for inosine, the addition of these nucleosides individually to SRBC-stimulated spleen cell cultures caused slight or no suppression of the PFC response.
Effects of ribavirin on PFC responses of T celldepleted spleen cell populations. The capacity of ribavirin to exert both positive and negative influences on primary and secondary antibody responses suggests a selective interference with different lymphocyte subpopulations. T cell-depleted spleen cell cultures were used to assess the direct effects of ribavirin on B cell responses ( Table 2 ). These responses were obtained by measuring LPS-specific PFC responses, uninfluenced by T cells. After T cells were depleted by monoclonal anti-Thy 1.2 IgM antibody and complement, C57BL/6 spleen cells generated an adjusted mean response of 200 PFC per 106 cells. The addition of 0.1 or 1 jig of ribavirin failed to enhance PFC responses; in fact, 1 ,ug suppressed PFC responses significantly (56%; P = 0.05). The addition of 10 ,ug of ribavirin inhibited PFC responses to less than 1% of the control responses. In parallel cultures (Table 2) , 1 ,ug of ribavirin enhanced LPS-and SRBCspecific PFC responses of untreated C57BL/6 spleen cells.
Ribavirin interference with suppressor T cell generation. Murine splenic PFC responses are suppressed by the addition of mitogenic concentrations of ConA at culture initiation but are enhanced if the addition of ConA is delayed until 48 h thereafter. These effects result from nonspecific activation of a large number of suppressor T cells and helper T cells, respectively (4, 28) . Initial experiments demonstrated that exposure of spleen cells to 1 ,ug of ConA or 1 ,ug of ribavirin 48 to 72 h after culture initiation moderately enhanced IgM PFC responses, whereas the simultaneous addition of 1 pug of ribavirin and 1 VOL. 22, 1982 ,ug of ConA resulted in an increase in the PFC response greater than that observed with ConA or ribavirin alone. In contrast, low doses (1 to 2 rag) of ribavirin appeared to counteract the suppressive effects of ConA when spleen cells were treated at culture initiation (data not shown). These results suggested that ribavirin did not interfere with the activation of helper T cells but inhibited the generation of suppressor T cells. More direct evidence for this hypothesis was obtained in the following experiment. Normal spleen cells were incubated for 24 h with or without ConA and various amounts of ribavirin. Cells were recovered, washed, counted, and transferred to newly initiated spleen cell cultures stimulated with SRBC. Data presented in Fig. 5 demonstrate that PFC responses in cultures receiving 105 ConA-activated spleen cells were markedly lower than in cultures receiving the same number of unstimulated spleen cells and that spleen cells activated in the presence of ConA and 1 or 10 ,ug of ribavirin possessed progressively less inhibitory activity.
The capacity of ribavirin to selectively interfere with the proliferative responses of lymphocyte subpopulations was examined by using spleen cell cultures stimulated with mitogenic concentrations of ConA or LPS. The data in Table 3 indicate that ribavirin suppressed not only the proliferative response of T cells to ConA stimulation but also suppressed the B cell response to LPS stimulation. It is particularly noteworthy, however, that 0.5 and 1 ,ug of ribavirin, amounts which enhanced PFC responses, inhibited proliferation induced by ConA without altering the response to LPS. Statistical analysis showed that these results were significant at the P < 0.001 level, indicating a greater sensitivity of ConA-activated spleen cells to ribavirin. DISCUSSION Although ribavirin has been used successfully for the treatment of naturally acquired and experimentally induced viral infections of humans and laboratory animals, only recently has it been found to possess immunoregulatory activity. When given to mice after antigen administration, ribavirin suppresses primary PFC responses and memory cell generation without apparent lymphocytotoxicity (19) . Other studies from this laboratory have shown that ribavirin stimulates serum hemagglutination inhibition antibody responses when administered as an aerosol to human volunteers acutely ill with influenza A virus infections (12) . By using an in vitro system, the present investigation was designed to examine the capacity of ribavirin to modulate antibody responses, to identify its cellular targets, and to determine its mechanism(s) of action. The results show that,. depending on the dose and duration of drug exposure, ribavirin may moderately enhance or entirely inhibit the generation of PFC responses. The modulation of PFC responses to both T cell-dependent (SRBC) and T cell-independent (LPS) antigens over an extremely narrow range of ribavirin concentrations suggests that these effects are mediated by a similar mechanism acting on at least two distinct cell types. It is unlikely that ribavirin interferes with the fuinc- (Table 2 ), inhibited T cell proliferation but not B cell proliferation (Table 3) , and blocked the generation of mitogen-induced suppressor T cells (Fig. 5 (8, 16, 26) . Lowe et al. monitored the metabolic effects of ribavirin on RK-13 cells and tumor cell lines and determined that although ribavirin inhibited the rate of growth, decreases in cell viability only occurred when doses of 500 to 1,000 ,ug/ml were used (13) .
The suppression of PFC responses by ribavirin was almost always accompanied by a significant loss of viable spleen cells. Reductions in viable cell recoveries were conspicuous when 5 txg of ribavirin was added to spleen cell cultures for 5 days or when 10 ,ug of ribavirin was added for as short a period as 24 h. In addition, the inability of guanosine to inhibit suppression by 10 ,ug of ribavirin after 12 h suggests that cytotoxicity contributes in an important way to immunosuppressive activity. Just why lymphocytes are more susceptible to ribavirin than other cell types may be because of several unique characteristics of their purine metabolism. Inhibition of inosine monophosphate dehydrogenase by ribavirin in all cells leads to a rapid loss of guanosine nucleotides; however, the limited capacity of lymphocytes to synthesize GMP from the de novo purine pathway may result in prolonged GMP deprivation (13, 22, 25) . Moreover, inhibition of inosine monophosphate syn-thesis by ribavirin would also be expected to cause accumulation of inosine, hypoxanthine, and other intermediates of the purine interconversion pathway. It is of considerable interest that ribavirin-treated human lymphoblasts secrete inosine and hypoxanthine extracellularly (29) and that the addition of inosine to murine spleen cell suspensions inhibited PFC responses (Table 1 ). In addition, intracellular accumulation of deoxyinosine, deoxyguanosine, and deoxyadenosine has recently been shown to be lymphocytotoxic in vitro and is thought to be responsible for the severe immunological dysfunction observed in T and B lymphocytes of patients with adenosine deaminase and purine nucleoside phosphorylase deficiencies (1, 6, 7) . ACKNOWLEDGMENTS This work was supported in part by Public Health Service contract DE-72400 from the National Institutes of Health, grant IM-138A from the American Cancer Society, and a grant from Viratek, Inc., Covina, Calif.
